Difference between revisions 7212881 and 7212883 on simplewiki

< previous diff
next diff >
Alvotech
{{Infobox company
| name = Alvotech
| industry = [[​​​Biopharmaceuticals]]
| founded = 2013<ref>{{cite web |title=Alvotech and STADA Agree on Strategic Biosimilar Partnership |url=https://www.bloomberg.com/press-releases/2019-11-06/alvotech-and-stada-agree-on-strategic-biosimilar-partnership |website=Bloomberg.com |language=en |date=6 November 2019}}</ref>
| key_people = ​​​Robert Wessman, Chairman<br/>Mark Levick, CEO
(contracted; show full)
 
==History==
Alvotech was founded in 2013 by the chairman and chief executive of Alvogen, Robert Wessman.<ref>{{cite web |title=ABDİ İBRAHİM AND ALVOTECH ENTER STRATEGIC PARTNERSHIP IN BIOTECHNOLOGY |url=https://www.cphi-online.com/abdi-ibrahim-and-alvotech-enter-strategic-news085050.html |website=www.cphi-online.com}}</ref> Shortly after its launch, the company announced its strategy to invest in the development and manufacturing of a portfolio of biosimilar monoclonal 
[[antibodies]].<ref>{{cite web |title=Growth story - Alvotech |url=http://www.alvotech.com/company/growth-story |archive-url=http://web.archive.org/web/20160612025127/http://www.alvotech.com/company/growth-story |archive-date=12 June 2016}}</ref><ref>{{cite web |title=Alvotech, JAMP Pharma Ink Biosim Deal |url=https://www.contractpharma.com/contents/view_breaking-news/2020-01-15/alvotech-jamp-pharma-ink-biosim-deal/ |website=Contract Pharma}}</ref>
 
In 2014, the development of new products was initiated, further enhancing Alvotech’s pipeline of biosimilar candidates. The company entered a partnership with Finesse Solutions, which provided Alvotech with scalable, flexible and cost-effective laboratory and manufacturing technology via its turnkey SmartFactory® GMP manufacturing platform suite.<ref>{{cite web |title=Single-Use Bioprocessing - US |url=http://www.finesse.com/company/press-room/news/2014/03/alvotech-and-finesse-announce-exciting-bio-manufacturing-collaboration/ |website=www.thermofisher.com |language=en}}</ref>
 
In 2016, Alvotech acquired German biopharmaceutical development company [[Baliopharm]].<ref>{{cite web |title=Alvotech acquires Baliopharm |url=https://www.manufacturingchemist.com/news/article_page/Alvotech_acquires_Baliopharm/118291 |website=www.manufacturingchemist.com}}</ref> The company opened its research and development centre in the Science Park of the University of Iceland, Reykjavík, at the start of June that year.<ref>{{cite web |title=Alvotech grand opening in Reykjavik |url=http://www.invest.is/press--media/news/invest/alvotech-grand-opening-in-reykjavik-today/234 |website=www.invest.is}}</ref><ref>{{cite web |title=R&D - Alvotech |url=http://www.alvotech.com/research-and-development |archive-url=http://web.archive.org/web/20161024194549/http://www.alvotech.com/research-and-development |archive-date=24 October 2016}}</ref>

==References==
{{Reflist}}

[[Category:2013 establishments]]
[[Category:Establishments in Iceland]]